At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
PF-06651600 30 mgdrug
Likely dose
PF-06651600 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, NON-RANDOMIZED, OPEN LABEL, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF 06651600 IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN HEALTHY SUBJECTS WITH NORMAL HEPATIC FUNCTION
In Brief
A Phase 1 clinical trial evaluating PF-06651600 30 mg for Hepatic Impairment and Healthy Participants. Completed, enrolled 18 participants across 2 sites.
Detailed Summary
The purpose of this study is to characterize the effect of hepatic impairment on the pharmacokinetic(s) (PK) of PF-06651600 following administration of multiple once daily doses of PF-06651600. The safety and tolerability of PF-06651600 will also be evaluated in this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Impairment, Healthy Participants
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartJul 2019
Primary CompletionMar 2020
TodayJul 2026
First PostedJul 11, 2019
Enrollment StartJul 19, 2019
Primary CompletionMar 5, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.0 years ago
Interventions
PF-06651600 30 mgdrug
PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.